Compare · CF vs EVGN
CF vs EVGN
Side-by-side comparison of CF Industries Holdings Inc. (CF) and Evogene Ltd (EVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CF and EVGN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CF is the larger of the two at $17.44B, about 2705.0x EVGN ($6.4M).
- Over the past year, CF is up 23.1% and EVGN is down 43.2% - CF leads by 66.3 points.
- EVGN has been more active in the news (6 items in the past 4 weeks vs 3 for CF).
- CF has more recent analyst coverage (25 ratings vs 4 for EVGN).
- Company
- CF Industries Holdings Inc.
- Evogene Ltd
- Price
- $113.47-3.45%
- $0.61-3.48%
- Market cap
- $17.44B
- $6.4M
- 1M return
- -5.37%
- -20.32%
- 1Y return
- +23.14%
- -43.19%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 4
CF Industries Holdings Inc.
CF Industries Holdings, Inc. manufactures and sells hydrogen and nitrogen products for clean energy, fertilizer, emissions abatement, and other industrial applications worldwide. Its principal products include anhydrous ammonia, granular urea, urea ammonium nitrate, and ammonium nitrate products. The company also offers diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia products; and compound fertilizer products with nitrogen, phosphorus, and potassium. It primarily serves cooperatives, independent fertilizer distributors, traders, wholesalers, and industrial users. The company was founded in 1946 and is headquartered in Deerfield, Illinois.
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Latest CF
- EVP and CFO Scribner Andrew was granted 6,464 shares (SEC Form 4)
- SEC Form 3 filed by new insider Scribner Andrew
- SEC Form 144 filed by CF Industries Holdings Inc.
- SEC Form 10-Q filed by CF Industries Holdings Inc.
- CF Industries Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CF Industries Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CF Industries Holdings, Inc. Reports First Quarter 2026 Net Earnings of $615 Million, Adjusted EBITDA of $983 Million
- CF Industries Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Andrew T. Scribner Elected Executive Vice President and Chief Financial Officer of CF Industries Holdings, Inc.
- CF Industries Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest EVGN
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- SEC Form 424B3 filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- Evogene Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene to Present at the 24th Schrödinger European User Group Meeting
- Evogene Schedules First Quarter 2026 Financial Results Release
- SEC Form EFFECT filed by Evogene Ltd
- SEC Form 3 filed by new insider Ravzin Polina
- SEC Form EFFECT filed by Evogene Ltd